TD Cowen analyst Charles Rhyee raised the firm’s price target on BrightSpring Health (BTSG) to $46 from $42 and keeps a Buy rating on the shares as part of a Q4 earnings preview. The firm sees continued momentum in Q4 for the company due to “strong” specialty generics trends.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $46 from $40 at BMO Capital
- Wells says ‘Great Healthcare Plan’ lacks new onerous proposals
- BrightSpring Health price target raised to $45 from $42 at Mizuho
- BrightSpring Health price target raised to $43 from $39 at Wells Fargo
- Klaviyo, Wingstop among Stephens Best Ideas for 2026